Article
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.
European journal of heart failure - 1 Jul 2023
Anker Stefan D, Usman Muhammad Shariq, Anker Markus S, Butler Javed, Böhm Michael, Abraham William T, Adamo Marianna, Chopra Vijay K, Cicoira Mariantonietta, Cosentino Francesco, Filippatos Gerasimos, Jankowska Ewa A, Lund Lars H, Moura Brenda, Mullens Wilfried, Pieske Burkert, Ponikowski Piotr, Gonzalez-Juanatey Jose R, Rakisheva Amina, Savarese Gianluigi, Seferovic Petar, Teerlink John R, Tschöpe Carsten, Volterrani Maurizio, von Haehling Stephan, Zhang Jian, Zhang Yuhui, Bauersachs Johann, Landmesser Ulf, Zieroth Shelley, Tsioufis Konstantinos, Bayes-Genis Antoni, Chioncel Ovidiu, Andreotti Felicita, Agabiti-Rosei Enrico, Merino Jose L, Metra Marco, Coats Andrew J S, Rosano Giuseppe M C
Abstract excerpt
Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions. Thus, in addition to treatment with sodium-glucose cotransporter 2 inhibitors...
Read the complete abstract on PubMed